Clinical Trials To Advance Therapies For Cardiovascular Disease In Type 1 Diabetes Grant

Clinical Trials To Advance Therapies For Cardiovascular Disease In Type 1 Diabetes Grant

Status: ACTIVE
Funder: Breakthrough T1D ( Formally JDRF International)
Amount: Up to US $3,000,000
Last Updated: September 16, 2025

Summary

Breakthrough T1D is dedicated to improving cardiovascular outcomes for individuals with type 1 diabetes (T1D). This funding opportunity aims to support clinical trials that evaluate innovative therapies for cardiovascular disease (CVD) in T1D patients. Grants of up to $3 million will be awarded over three years to encourage research that addresses the unmet needs of this population, enhancing both treatment options and care access.

Overview

Breakthrough T1D Founded in 1970 by families whose loved ones had been diagnosed with type 1 diabetes (T1D), Breakthrough T1D is a tax-exempt nonprofit 501(c)3 organization. We are opening doors that were once closed by T1D diagnosis. We lead the way to more effective solutions by connecting the brightest minds to advance treatments, influence policy, and improve access to care.​ By driving innovation forward, Breakthrough T1D will make type 1 diabetes a condition of the past. Clinical trials to advance therapies for cardiovascular disease in type 1 diabetes Summary The goal of this funding opportunity is to advance therapies to improve cardiovascular outcomes in people with established type 1 diabetes (T1D).This funding opportunity will prioritize clinical trials evaluating promising therapies, whether repositioned, repurposed, in development, or already approved, for cardiovascular disease (CVD) in people with T1D.This initiative will award grants for clinical studies to academic investigators and industry partners of up to $3,000,000.00 over 3 years. Funding Opportunity Description Breakthrough T1D is committed to the development of therapies to improve clinical outcomes in people with type 1 diabetes (T1D). Cardiovascular disease (CVD) is the primary cause of morbidity and mortality in people with T1D. There is currently a lack of targeted therapies for CVD approved for use by people with T1D, in part because people with T1D are seldom included in drug trials for these diabetic complications. To fill this gap, Breakthrough T1D invites applications for clinical trials to advance therapies to improve CVD outcomes in T1D.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.